Sarcomas Metastatic to the Liver: Response and Survival after Cisplatin, Doxorubicin, Mitomycin-C, Ethiodol, and Polyvinyl Alcohol Chemoembolization

Rajan, Dheeraj K.; Soulen, Michael C.; Clark, Timothy W.I.; Baum, Richard A.; Haskal, Ziv J.; Shlansky-Goldberg, Richard D.; Freiman, David B.

doi:10.1016/s1051-0443(07)61824-7

Cited by 83 publications

(36 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[11][12][13] Of late, studies have demonstrated successful application to a variety of secondary hepatic malignancies, including metastasis from neuroendocrine neoplasm, breast cancer, or sarcoma. [14][15][16][17] To our knowledge, the use of TACE for the treatment of hepatic recurrence after curative surgery for pancreatic adenocarcinoma has yet to be reported. Therefore, the aim of the current study was to evaluate the clinical effectiveness of TACE in patients with hepatic recurrence after curative resection for pancreatic adenocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

Transcatheter Arterial Chemoembolization for Hepatic Recurrence after Curative Resection of Pancreatic Adenocarcinoma

Kim¹,

Choi²,

Yoon³

et al. 2010

Gut Liver

View full text Add to dashboard Cite

Background/Aims: Despite curative resection, hepatic recurrences cause a significant reduction in survival in patients with primary pancreatic adenocarcinoma. Transcatheter arterial chemoembolization (TACE) has recently been used successfully to treat primary and secondary hepatic malignancy. Methods: Between 2003 and 2008, 15 patients underwent TACE because of hepatic recurrence after curative resection of a pancreatic adenocarcinoma. The tumor response was evaluated based on computed tomography scans after TACE. The overall duration of patient survival was measured. Results: After TACE, a radiographically evident response occurred in six patients whose tumors demonstrated a tumor blush on angiography. Four patients demonstrated stabilization of a hypovascular mass. The remaining five patients demonstrated continued progression of hypovascular hepatic lesions. The median survival periods from the time of diagnosis and from the time of initial TACE were 9.6 and 7.5 months, respectively. Conclusions: TACE may represent a viable therapeutic modality in patients with hepatic recurrence after curative resection of pancreatic adenocarcinoma. (Gut Liver 2010;4: 384-388)

show abstract

Section: Introductionmentioning

confidence: 99%

Transcatheter Arterial Chemoembolization for Hepatic Recurrence after Curative Resection of Pancreatic Adenocarcinoma

Kim¹,

Choi²,

Yoon³

et al. 2010

Gut Liver

View full text Add to dashboard Cite

show abstract

“…[15][16][17] TACE has also been successfully performed in patients with hepatic metastasis from neuroendocrine neoplasm, colorectal cancer, ocular melanoma, or soft-tissue sarcoma. [18][19][20][21][22] Given that ICC arises within the intrahepatic biliary tree, hepatic intra-arterial chemotherapy was believed to offer a new effective treatment for patients with unresectable ICC. 2 To our knowledge, there have been only a few studies 2,23 reporting the efficacy of TACE for ICC; however, these studies 2,23 have had the disadvantage of small study populations, ie, usually fewer than 20 patients.…”

mentioning

confidence: 99%

Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma

Kim

Yoon

Sung

et al. 2008

Cancer

107

View full text Add to dashboard Cite

BACKGROUND.The role of transcatheter arterial chemoembolization (TACE) or transcatheter arterial chemoinfusion (TACI) for unresectable intrahepatic cholangiocarcinoma (ICC) has recently been questioned. The aim of the study was to evaluate the clinical efficacy of TACE or TACI in patients with unresectable ICC and to identify prognostic factors associated with clinical success.METHODS.From 1997 to 2007, 49 patients with unresectable ICC were treated with TACE (n = 124) or transcatheter arterial chemoinfusion (TACI) (n = 96). Tumor response was evaluated based on computed tomography scans obtained 1 month to 3 months after TACE or TACI. Factors associated with clinical success were evaluated using multivariate logistic regression analysis. Factors associated with the survival period were evaluated using multivariate Cox regression analysis.RESULTS.After treatment, 27 (55%) of the patients showed radiographic response. Multivariate analysis confirmed that tumor vascularity (odds ratio [OR], 31.2; P = .002) was the only independent factor associated with radiographic response. The median and mean survival periods in our study patients were 12 and 24 months. Multivariate Cox regression analyses showed that tumor size (OR, 2.64; P = .048), tumor vascularity (OR, 13.5; P < .001), and the Child‐Pugh class (OR, 3.65; P = .014) were the independent factors associated with the length of the survival period.CONCLUSIONS.Hepatic intra‐arterial chemotherapy is well tolerated and may be effective to prolong survival of patients with unresectable ICC. Tumor vascularity is significantly associated with radiographic response. Large tumor size, tumor hypovascularity, and Child‐Pugh class B were poor prognostic factors for determining the patient survival period. Cancer 2008. © 2008 American Cancer Society.

show abstract

“…Fifteen studies 18,[46][47][48][49][50][51][52][53][54][55][56][57][58] were included (of which nine were trials, one controlled) that reported on treatments other than imatinib for advanced GIST. In only one small study was cKIT status analysed (retrospectively, by Ryan and co-workers 46 ).…”

Section: Results Reported In Studies Of Alternative Treatmentsmentioning

confidence: 99%

“…Of these, both imatinib trials used CTC version 2.0, while one trial 48 used CTC version 3.0. Four trials used CTC without giving the version number.…”

Section: Papermentioning

confidence: 99%

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

Wilson

Connock²,

Song³

et al. 2005

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: D Peake has been paid by Novartis to give one lecture on GIST and was sponsored to attend the Third International Symposium on GIST. Other than this, members of the review team at the University of Birmingham have no any pecuniary relationship with sponsors, specific or non-specific. J Raftery is Director of the NCCHTA but he was not involved in the editorial process for this report. HTA Published July 2005This report should be referenced as follows: NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technolo...

show abstract

Sarcomas Metastatic to the Liver: Response and Survival after Cisplatin, Doxorubicin, Mitomycin-C, Ethiodol, and Polyvinyl Alcohol Chemoembolization

Cited by 83 publications

References 23 publications

Transcatheter Arterial Chemoembolization for Hepatic Recurrence after Curative Resection of Pancreatic Adenocarcinoma

Transcatheter Arterial Chemoembolization for Hepatic Recurrence after Curative Resection of Pancreatic Adenocarcinoma

Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

Contact Info

Product

Resources

About